Home   Business   Article

Subscribe Now

Feedback’s £2m is tagged for the launch of Bleepa

Medical-grade images on Bleepa
Medical-grade images on Bleepa

Specialist medical imaging company Feedback has conditionally raised £2million – just weeks before its Bleepa app is launched to the healthcare services sector.

The investment – from individuals and institutions due to be named later this month – represents around 30 per cent of the company’s enlarged share capital, according to CEO Tom Oakley.

“We’re very pleased,” Tom said of the incoming funding. “This helps us to make the most of the opportunity we’ve been working towards.”

Bleepa is being launched at NHS Expo in Manchester on September 4/5. The technology allows medical grade imaging to be made available on a mobile phone or tablet. According to an article published in BMJ Innovations, 97 per cent of hospital doctors routinely use WhatsApp to communicate about patients, and Bleepa will ensure messaging can come with high-grade medical imaging.

Tom Oakley, CEO, Feedback
Tom Oakley, CEO, Feedback

“Bleepa is securely downloadable from our site via a secure link sent to the medical person,” says Tom. “The hospital pays for your permissions. This is a tool everyone can use across the NHS – that’s the target. Bleepa broadens access to imaging data, and there’s no clinical type where there wouldn’t be an application.”

The app is expected to cost £10 a month.

“All of the £2million is earmarked for the runway to get Bleepa up and running and out into the market,” continues Tom. “This is effectively seed funding for an entirely new product.”

Bleepa is an evolution of Cadran, the current medical imaging storage facility used in the healthcare sector. Cadran was launched 17 years ago.

“We believe Bleepa is set to transform the outlook for the company and could change the way medical images are communicated in everyday clinical practice on mobile devices and laptops.” said Feedback’s non-executive chairman, Dr Alastair Riddell.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More